Given the known impact of XPO1 inhibition on the self-renewal of leukemia-initiating cells (LICs) and the high expression of XPO1 in FLT3-ITD patients [9], combination of selinexor with FLT3 inhibitors could synergistically impact disease burden for FLT3-ITD AML patients and further extend the antileukemic benefit to the LIC compartment [10]. The gene discussed is FLT3; the disease is leukemia.